CLINICAL_TRIALS
trial_result
· 2024-03-06
Clinical Trial Update: A Study Of PF-04449913 Administered Alone In Select Solid Tumors [Phase 1]
Summary
Phase 1 trial evaluating PF-04449913 as a single agent in select solid tumors has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2024-03-06